Business
AEON Biopharma Announces Execution of Exchange Agreement with Daewoong
- AEON and Daewoong Pharmaceutical have executed definitive documentation to exchange $15 million of notes plus accrued interest into new equity, $1.5 million of new notes due 2030, and a cash-exercise warrant for 8 million shares of common stock – - Exchange remains subject to shareholder approval - IRVINE, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company seeking accelerated and full-label U.S. market ent
About this update from Aeon Biopharma, Inc.
[{"type":"image","alt":"AEON Biopharma Inc","displaySize":"","headline":null,"caption":"AEON Biopharma Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":132,"height":32,"url":"https://media.zenfs.com/en/globenewswire.com/a19efd6bbb6fc208e65cef7e4f3708c5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/L69JurVw8dq7IznuR4WbIA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTUxO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/a19efd6bbb6fc208e65cef7e4f3708c5","width":132,"height":32}},"lazy":false},{"type":"text","content":"- AEON and Daewoong Pharmaceutical have executed definitive documentation to exchange $15 million of notes plus accrued interest into new equity, $1.5 million of new notes due 2030, and a cash-exercise warrant for 8 million shares of common stock –","length":248,"tagName":"p"},{"type":"text","content":"- Exchange remains subject to shareholder approval - ","length":52,"tagName":"p"},{"type":"text","content":"IRVINE, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company seeking accelerated and full-label U.S. market entry by developing ABP-450 (prabotulinumtoxinA) as a BOTOX (onabotulinumtoxinA) biosimilar, today announced that the Company and Daewoong Pharmaceutical (“Daewoong”) have entered into a definitive agreement to exchange the Company’s $15 million of convertible notes plus accrued interest into new equity, $1.5 million of new notes due 2030, and a cash-exercise warrant for 8 million shares of common stock, on the same terms as the warrants in the private placement financing announced in November 2025 (the “Exchange”). The cash-exercise warrants, if exercised, represent over $8 million in potential additional cash proceeds to AEON.","length":831,"tagName":"p"},{"type":"text","content":"“We are pleased to report the signing of definitive documentation for our exchange of Daewoong’s existing AEON-issued debt,” said Rob Bancroft, President & Chief Executive Officer of AEON. “While the transaction remains subject to a shareholder vote, this is an impotant step forward in deleveraging the company and we believe sets the stage for continued progress for our ABP-450 biosimiliar strategy in 2026.”","length":415,"tagName":"p"},{"type":"text","content":"Previously, AEON and Daewoong entered into a binding term sheet contemplat...